Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002.

J Toxicol Environ Health A. 2010;73(24):1665-77. doi: 10.1080/15287394.2010.519317.
Gallagher CM1, Goodman MS.
Author information
1PhD Program in Population Health and Clinical Outcomes Research, Stony Brook University Medical Center, State University of New York at Stony Brook, Stony Brook, New York, USA. cmgallagher@notes.cc.sunysb.edu

Abstract
Universal hepatitis B vaccination was recommended for U.S. newborns in 1991; however, safety findings are mixed. The association between hepatitis B vaccination of male neonates and parental report of autism diagnosis was determined. This cross-sectional study used weighted probability samples obtained from National Health Interview Survey 1997-2002 data sets. Vaccination status was determined from the vaccination record. Logistic regression was used to estimate the odds for autism diagnosis associated with neonatal hepatitis B vaccination among boys age 3-17 years, born before 1999, adjusted for race, maternal education, and two-parent household. Boys vaccinated as neonates had threefold greater odds for autism diagnosis compared to boys never vaccinated or vaccinated after the first month of life. Non-Hispanic white boys were 64% less likely to have autism diagnosis relative to nonwhite boys. Findings suggest that U.S. male neonates vaccinated with the hepatitis B vaccine prior to 1999 (from vaccination record) had a threefold higher risk for parental report of autism diagnosis compared to boys not vaccinated as neonates during that same time period. Nonwhite boys bore a greater risk.

PMID: 21058170 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/21058170